• DOI:10.1002/PPUL.1125
• Corpus ID: 30108514

Efficacy and safety of aerosolized tobramycin in cystic fibrosis

@article{Pai2001EfficacyAS,
  title={Efficacy and safety of aerosolized tobramycin in cystic fibrosis},
  author={Vinita B. Pai and Milap C. Nahata},
  journal={Pediatric Pulmonology},
  year={2001},
  volume={32}
}

• V. Pai, M. Nahata
• Published 1 October 2001
• Medicine
• Pediatric Pulmonology

Aerosolized tobramycin has been extensively used in cystic fibrosis (CF) patients in order to directly deliver the antibiotic to the endobronchial site of infection, and decrease toxicity by limiting systemic absorption. Aerosolized tobramycin doses ranging from 80 mg twice or three times daily to 600 mg three times daily have been used in various clinical trials. At an 80‐mg dose, preservation of pulmonary function with little or no improvement over the baseline was reported. Tobramycin, nebulized at 600 mg three times daily, significantly improved clinical and pulmonary functions and reduced the density of Pseudomonas aeruginosa in the sputum. No ototoxicity or nephrotoxicity was reported at either dose.